Sound Wave Innovation Co., Ltd. (SWI), a pioneering medical technology company focused on developing innovative treatments for dementia and cardiovascular diseases, today announced changes to its executive leadership team.

■New Leadership to Drive Next Phase of Growth
SWI is developing a minimally invasive treatment platform using low-intensity pulsed ultrasound (LIPUS) and shock wave catheter ablation system (SWCS). The company’s goal is to bring revolutionary treatments to patients suffering from conditions such as dementia, severe angina pectoris, and arrhythmia.

SWI’s LIPUS-AD therapy device for early-stage Alzheimer’s disease has demonstrated promising results in a physician-led exploratory clinical trial completed in 2022. The trial showed high safety and suggested potential efficacy of the device. Based on these results, the LIPUS-AD was designated as the first “Breakthrough Medical Device” by the Ministry of Health, Labor and Welfare in Japan on September 30, 2022.

In October 2023, SWI initiated a confirmatory clinical trial (Phase 3 equivalent) to further evaluate the efficacy of LIPUS-AD. The trial reached its target enrollment in November 2024, and the company plans to pursue regulatory approval in 2027.

SWI’s founder, Prof. Hiroaki Shimokawa, will assume the role of Representative Director, President, CEO, and CMO. Mr. Tokihiko Shimizu, who has served as a Director of the company, will assume the role of Representative Director. Both individuals bring a wealth of experience and expertise to their new roles, and their leadership will be instrumental in accelerating the company’s growth and achieving its mission.

■New Executive Appointments
Hiroaki Shimokawa, MD, PhD – Representative Director, President, CEO, and CMO (Chief Medical Officer)
Tokihiko Shimizu – Representative Director
Takumi Shibata – Executive Director (New Appointment)

■Executive Biographies
Hiroaki Shimokawa, MD, PhD
Prof. Shimokawa is a renowned cardiologist and researcher. He graduated from Kyushu University School of Medicine in 1979 and received his PhD in 1985. He has held faculty positions at Kyushu University and Tohoku University, where he served as Professor of Cardiovascular Medicine. He founded SWI in 2020 and served as the Chairman and CMO

Tokihiko Shimizu
Mr. Shimizu has extensive experience in the financial industry. He joined the Ministry of Health and Welfare in 1987 and later held senior positions at Japan Post Bank and JP Investment Co., Ltd. He is a founding partner of Fiducia, Inc. and has served as a Director of SWI since 2023.

Takumi Shibata
Mr. Shibata has a distinguished career in the financial industry. He joined Nomura Securities Co., Ltd. in 1976 and held various leadership positions, including President of Nomura International and COO of Nomura Holdings, Inc. He also served as Chairman of Nikko Asset Management Co., Ltd. He is a founding partner of Fiducia, Inc.

Contact :
Sound Wave Innovation Co., Ltd.
mail：info@sw-innovation.com